🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS Β· Real-Time Price Β· USD
0.8200
-0.1353 (-14.16%)
At close: Nov 20, 2026, 4:00 PM EST
0.8398
+0.0198 (2.41%)
After-hours: Nov 20, 2026, 7:58 PM EST

Fractyl Health Earnings Call Transcripts

Fiscal Year 2026

  • REMAIN-1 met its six-month endpoint, with Revita participants retaining ~80% of weight lost on tirzepatide. Cash is expected to fund the De Novo submission and Q1 2027 pivotal data, while restructuring targets a ~50% reduction in quarterly operating cash spending.

  • Study update

    Revita met its six-month REMAIN-1 co-primary comparison, retaining 80% of GLP-1-induced weight loss versus 67% with sham (P=0.0023). Twelve-month results are expected in Q1 2027, with De Novo preparation and access planning underway.

  • EGM 2026

    Stockholders approved a proposal granting the board authority to enact a reverse stock split at a ratio between 1-for-5 and 1-for-15. Quorum was achieved, and no questions were submitted. Final voting results will be published in a Form 8-K.

  • Revita is positioned as a durable, outpatient solution for post-GLP-1 weight maintenance, with pivotal data and a regulatory filing expected soon. The commercial strategy targets top bariatric centers, leveraging existing infrastructure and a favorable safety profile. CMS policy and early coverage for Breakthrough Devices could be major growth drivers.

  • Durable weight maintenance after GLP-1 discontinuation is a critical unmet need, addressed by Revita's device-based approach, which has shown strong efficacy and safety in clinical studies. Regulatory and commercial strategies are aligned for a potential U.S. launch in 2027, with pivotal data expected in early Q4 2026.

  • Status update

    Post-GLP-1 weight regain is a major unmet need, with millions of patients lacking durable maintenance options. Revita, a one-time endoscopic procedure, shows strong efficacy and safety, with a large addressable market and a focused commercialization plan targeting high-volume centers. Break-even is projected within 5-8 quarters post-launch, leveraging favorable reimbursement dynamics.

  • Durable therapies for obesity and diabetes are advancing, with Revita showing strong weight maintenance in clinical trials and pivotal data expected soon. Commercialization will focus on specialized centers, leveraging partnerships and existing clinical networks. Rejuva gene therapy is entering first-in-human trials this year.

  • Revita maintained over 80% of GLP-1-induced weight loss at one year with a strong safety profile, while pivotal trial data and a potential FDA De Novo submission are expected in Q4 2026. Cash runway extends into early 2027, supporting both Revita and Rejuva programs.

  • Study result

    One-year data from the REMAIN-1 midpoint cohort show Revita enables patients to maintain up to 84% of GLP-1-induced weight loss, with a favorable safety profile and minimal adverse events. Durable, drug-free weight maintenance is achievable, supporting broad outpatient use and strong patient demand.

  • AGM 2026

    The meeting covered board introductions, voting on director elections and auditor ratification, and outlined procedures for participation. Both proposals passed, with final results to be published soon. No questions were submitted during the Q&A.

  • Revita aims to provide a durable, non-pharmacologic weight maintenance solution for obesity and type 2 diabetes, with pivotal clinical data and a regulatory filing expected by year-end. The company is targeting a focused commercial launch and is well-funded into 2027, while also advancing its gene therapy pipeline.

  • Q1 2026 saw improved financials and strong clinical progress, with pivotal Revita trial data expected in early Q4 and Rejuva gene therapy advancing to first-in-human studies. Cash runway extends into early 2027, with no capital raise planned before pivotal data.

  • Study result

    Six-month data from the REMAIN-1 pilot show Revita significantly reduces post-GLP-1 weight regain, especially in high-risk patients, with strong safety and metabolic benefits. The pivotal study is fully enrolled and on track for top-line data and potential FDA submission in late 2026.

Fiscal Year 2025

Fiscal Year 2024